Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen
Sammanfattning
Melanoma is an aggressive form of skin cancer which is the cause of a great number of skin cancer-related deaths worldwide and about
300 deaths in Denmark. After several years of failure of treatment of metastatic melanoma, the development of BRAF- and later MEK inhibitors
was considered revolutionary. Treatment with BRAF inhibitors alone and especially in combination with a MEK inhibitor improves outcome for
patients with BRAF V600-mutated metastatic melanoma. However, even when treated with the combination of the inhibitors, many patients
develop acquired resistance within a year.